Anatomic response of occult choroidal neovascularization to intravitreal ranibizumab

A study by indocyanine green angiography

Giuseppe Querques, Thi Ha Chau Tran, Raimondo Forte, Lea Querques, Francesco Bandello, Eric H. Souied

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background To investigate changes in indocyanine green angiography (ICGA) features of occult choroidal neovascularization (CNV) after intravitreal ranibizumab injections. Methods We reviewed the charts of all consecutive patients with newly diagnosed occult CNV secondary to age-related macular degeneration (AMD) treated by intravitreal ranibizumab. In all patients, optical coherence tomography (OCT) and ICGA were performed at baseline, after 3 months and 12 months. Results Fifty-one eyes of 44 patients (ten males, 34 females, mean age 77.8±7.3 years) were included. Mean follow-up was 20.3±6.2 months. During the first 12 months, patients received 5.5±2.7 intravitreal ranibizumab injections. When compared with baseline, best-corrected visual acuity (BCVA) significantly improved at the 3-month follow-up visit (60.5 ±22.0 vs 50.9 ±20.7 letters, p=0.04), and stabilized at 12-month visit (55.7 ±18.2 letters; p=0.05). Central macular thickness (CMT) significantly improved during follow-up (229.0 ±54.7 ?m vs 281.0 ±61.3 ?m at baseline, p=0.003). An overall stabilization was observed on ICGA in both the lesion area (5.27±3.9 mm 2 at baseline vs 4.60±3.5 mm 2 at month 12, p=0.4), and greatest linear dimension (GLD 2.66± 1.2 mm at baseline vs 2.55±1.0 mm at month 12, p=0.3). Eight eyes (15.7%) showed CNV growth on ICGA (lesion area 3.98±3.2 mm2 at baseline vs 4.3±2.7 mm2 at month-12, p=0.6; GLD 2.11±1.0 mm at baseline vs 2.70±0.8 mm at month-12, p=0.05). Conclusion ICGA suggests that functional outcomes after intravitreal ranibizumab is related to CMT reduction rather than CNV regression.

Original languageEnglish
Pages (from-to)479-484
Number of pages6
JournalGraefe's Archive for Clinical and Experimental Ophthalmology
Volume250
Issue number4
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Choroidal Neovascularization
Indocyanine Green
Angiography
Intravitreal Injections
Optical Coherence Tomography
Macular Degeneration
Visual Acuity
Ranibizumab
Growth

Keywords

  • Age-related macular degeneration
  • Choroidal neovascularization
  • Fluorescein angiography
  • Indocyanine angiography
  • Optical coherence tomography
  • Ranibizumab

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience
  • Medicine(all)

Cite this

Anatomic response of occult choroidal neovascularization to intravitreal ranibizumab : A study by indocyanine green angiography. / Querques, Giuseppe; Tran, Thi Ha Chau; Forte, Raimondo; Querques, Lea; Bandello, Francesco; Souied, Eric H.

In: Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 250, No. 4, 04.2012, p. 479-484.

Research output: Contribution to journalArticle

@article{55243b82e1504bb599d497b4dbfd3e83,
title = "Anatomic response of occult choroidal neovascularization to intravitreal ranibizumab: A study by indocyanine green angiography",
abstract = "Background To investigate changes in indocyanine green angiography (ICGA) features of occult choroidal neovascularization (CNV) after intravitreal ranibizumab injections. Methods We reviewed the charts of all consecutive patients with newly diagnosed occult CNV secondary to age-related macular degeneration (AMD) treated by intravitreal ranibizumab. In all patients, optical coherence tomography (OCT) and ICGA were performed at baseline, after 3 months and 12 months. Results Fifty-one eyes of 44 patients (ten males, 34 females, mean age 77.8±7.3 years) were included. Mean follow-up was 20.3±6.2 months. During the first 12 months, patients received 5.5±2.7 intravitreal ranibizumab injections. When compared with baseline, best-corrected visual acuity (BCVA) significantly improved at the 3-month follow-up visit (60.5 ±22.0 vs 50.9 ±20.7 letters, p=0.04), and stabilized at 12-month visit (55.7 ±18.2 letters; p=0.05). Central macular thickness (CMT) significantly improved during follow-up (229.0 ±54.7 ?m vs 281.0 ±61.3 ?m at baseline, p=0.003). An overall stabilization was observed on ICGA in both the lesion area (5.27±3.9 mm 2 at baseline vs 4.60±3.5 mm 2 at month 12, p=0.4), and greatest linear dimension (GLD 2.66± 1.2 mm at baseline vs 2.55±1.0 mm at month 12, p=0.3). Eight eyes (15.7{\%}) showed CNV growth on ICGA (lesion area 3.98±3.2 mm2 at baseline vs 4.3±2.7 mm2 at month-12, p=0.6; GLD 2.11±1.0 mm at baseline vs 2.70±0.8 mm at month-12, p=0.05). Conclusion ICGA suggests that functional outcomes after intravitreal ranibizumab is related to CMT reduction rather than CNV regression.",
keywords = "Age-related macular degeneration, Choroidal neovascularization, Fluorescein angiography, Indocyanine angiography, Optical coherence tomography, Ranibizumab",
author = "Giuseppe Querques and Tran, {Thi Ha Chau} and Raimondo Forte and Lea Querques and Francesco Bandello and Souied, {Eric H.}",
year = "2012",
month = "4",
doi = "10.1007/s00417-011-1831-5",
language = "English",
volume = "250",
pages = "479--484",
journal = "Graefe's Archive for Clinical and Experimental Ophthalmology",
issn = "0721-832X",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Anatomic response of occult choroidal neovascularization to intravitreal ranibizumab

T2 - A study by indocyanine green angiography

AU - Querques, Giuseppe

AU - Tran, Thi Ha Chau

AU - Forte, Raimondo

AU - Querques, Lea

AU - Bandello, Francesco

AU - Souied, Eric H.

PY - 2012/4

Y1 - 2012/4

N2 - Background To investigate changes in indocyanine green angiography (ICGA) features of occult choroidal neovascularization (CNV) after intravitreal ranibizumab injections. Methods We reviewed the charts of all consecutive patients with newly diagnosed occult CNV secondary to age-related macular degeneration (AMD) treated by intravitreal ranibizumab. In all patients, optical coherence tomography (OCT) and ICGA were performed at baseline, after 3 months and 12 months. Results Fifty-one eyes of 44 patients (ten males, 34 females, mean age 77.8±7.3 years) were included. Mean follow-up was 20.3±6.2 months. During the first 12 months, patients received 5.5±2.7 intravitreal ranibizumab injections. When compared with baseline, best-corrected visual acuity (BCVA) significantly improved at the 3-month follow-up visit (60.5 ±22.0 vs 50.9 ±20.7 letters, p=0.04), and stabilized at 12-month visit (55.7 ±18.2 letters; p=0.05). Central macular thickness (CMT) significantly improved during follow-up (229.0 ±54.7 ?m vs 281.0 ±61.3 ?m at baseline, p=0.003). An overall stabilization was observed on ICGA in both the lesion area (5.27±3.9 mm 2 at baseline vs 4.60±3.5 mm 2 at month 12, p=0.4), and greatest linear dimension (GLD 2.66± 1.2 mm at baseline vs 2.55±1.0 mm at month 12, p=0.3). Eight eyes (15.7%) showed CNV growth on ICGA (lesion area 3.98±3.2 mm2 at baseline vs 4.3±2.7 mm2 at month-12, p=0.6; GLD 2.11±1.0 mm at baseline vs 2.70±0.8 mm at month-12, p=0.05). Conclusion ICGA suggests that functional outcomes after intravitreal ranibizumab is related to CMT reduction rather than CNV regression.

AB - Background To investigate changes in indocyanine green angiography (ICGA) features of occult choroidal neovascularization (CNV) after intravitreal ranibizumab injections. Methods We reviewed the charts of all consecutive patients with newly diagnosed occult CNV secondary to age-related macular degeneration (AMD) treated by intravitreal ranibizumab. In all patients, optical coherence tomography (OCT) and ICGA were performed at baseline, after 3 months and 12 months. Results Fifty-one eyes of 44 patients (ten males, 34 females, mean age 77.8±7.3 years) were included. Mean follow-up was 20.3±6.2 months. During the first 12 months, patients received 5.5±2.7 intravitreal ranibizumab injections. When compared with baseline, best-corrected visual acuity (BCVA) significantly improved at the 3-month follow-up visit (60.5 ±22.0 vs 50.9 ±20.7 letters, p=0.04), and stabilized at 12-month visit (55.7 ±18.2 letters; p=0.05). Central macular thickness (CMT) significantly improved during follow-up (229.0 ±54.7 ?m vs 281.0 ±61.3 ?m at baseline, p=0.003). An overall stabilization was observed on ICGA in both the lesion area (5.27±3.9 mm 2 at baseline vs 4.60±3.5 mm 2 at month 12, p=0.4), and greatest linear dimension (GLD 2.66± 1.2 mm at baseline vs 2.55±1.0 mm at month 12, p=0.3). Eight eyes (15.7%) showed CNV growth on ICGA (lesion area 3.98±3.2 mm2 at baseline vs 4.3±2.7 mm2 at month-12, p=0.6; GLD 2.11±1.0 mm at baseline vs 2.70±0.8 mm at month-12, p=0.05). Conclusion ICGA suggests that functional outcomes after intravitreal ranibizumab is related to CMT reduction rather than CNV regression.

KW - Age-related macular degeneration

KW - Choroidal neovascularization

KW - Fluorescein angiography

KW - Indocyanine angiography

KW - Optical coherence tomography

KW - Ranibizumab

UR - http://www.scopus.com/inward/record.url?scp=84861311253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861311253&partnerID=8YFLogxK

U2 - 10.1007/s00417-011-1831-5

DO - 10.1007/s00417-011-1831-5

M3 - Article

VL - 250

SP - 479

EP - 484

JO - Graefe's Archive for Clinical and Experimental Ophthalmology

JF - Graefe's Archive for Clinical and Experimental Ophthalmology

SN - 0721-832X

IS - 4

ER -